CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 304 enrolled
Drug / intervention
Duloxetine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02417935
NCT02417935Phase 4Completed
CompareCT.gov

A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain

Eli Lilly and Company·interventional·Posted Apr 16, 2015·Updated Sep 18, 2019

In Brief

A Phase 4 clinical trial evaluating Duloxetine, Pregabalin, and 1 other intervention for Diabetic Peripheral Neuropathic Pain. Completed, enrolled 304 participants.

Detailed Summary

The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Peripheral Neuropathic Pain
Countries--
CollaboratorsShionogi

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 16, 2015
Enrollment StartApr 1, 2015
Primary CompletionMay 13, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.2 years ago

Interventions

Duloxetinedrug

Administered orally

Pregabalindrug

Administered orally

Placebodrug

Administered orally